secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001372514-23-000112
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals appoints Carmine Stengone to Board of Directors
---------------------------------------------------------------------

- Carmine Stengone (President & CEO of Pipeline Therapeutics) appointed as independent Class I director; term to 2025 annual meeting.
- Stengone raised >$180M and executed a >$1B collaboration with Janssen; expertise in small molecules and neurodegenerative diseases.
- He will advise on strategic decisions and clinical development, notably for KIO-301 (retinitis pigmentosa candidate in ABACUS trial).
- Board determined independence under Nasdaq rules; compensation same as other non-employee directors.
- No arrangements, family relationships, or material transactions with the company since start of last fiscal year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000112/0001372514-23-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000112/kprx-20230801.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer